ZenaTech reports CAD $33M annualized revenue run rate

ZenaTech reported Q1 2026 revenue of CAD $8.3M, implying an illustrative annualized run rate of ~CAD $33M (8.3×4), alongside 705% year-over-year revenue growth. The company attributes performance to its Drone-as-a-Service model and multiple acquisitions contributing partial-year revenue, with full twelve-month run-rate expected later in fiscal 2026. Despite this growth narrative, InvestingPro notes the stock trades below fair value and analysts expect continued sales growth, with ongoing developments spanning AI drone products, an AI productivity platform beta, and Blue UAS certification efforts.

Analysis

The market should treat this as a quality-of-growth question, not a headline revenue print. ZENA’s reported run-rate is being lifted by partial-year acquisitions, which can support multiple expansion in a microcap only if those acquired assets are actually accretive to gross margin and cash flow after integration. If the deal cadence keeps outrunning disclosure, the equity is vulnerable to the usual roll-up penalty: investors eventually discount revenue that arrives with dilution, earnouts, and integration drag.

Second-order, the biggest near-term beneficiary is probably the small-cap drone/AI basket rather than the company itself. Any credible defense-certification progress or acquisition momentum can spill into AVAV, RCAT, and ONDS on sympathy flow, but the cleaner read-through is that ZENA is trying to buy its way into scale while competitors with real backlog and procurement visibility remain better quality assets. The loser is anyone underwriting this on an annualized run-rate multiple without checking share count growth or whether the new businesses are actually higher margin than the legacy mix.

Catalysts split by horizon: 1-3 months is about whether LOIs become financed, signed deals and whether Blue UAS progress turns from paperwork into approval; 6-18 months is about whether this becomes a sustainable platform or a serial-acquisition treadmill. The thesis is falsified if next quarter shows decelerating sequential growth, lower gross margin, or materially higher dilution versus revenue. Absent cleaner organic metrics, this is more of a watchlist name than a high-conviction long.

Key Decisions for Investors

• Fade strength in ZENA over the next 1-2 weeks if the stock gaps on this release; use any 10-15% rally as an opportunity to short or reduce exposure, with a stop only if management converts non-binding deal pipeline into signed, financed transactions.
• Pair trade for 1-3 months: long AVAV (or ONDS for higher beta) vs short ZENA. The long leg has clearer procurement/certification optionality; the short leg is a roll-up story that still needs proof of accretion. Falsify if ZENA posts explicit organic growth and margin expansion.
• Do not add to PLCKF solely on the 12% Plurilock stake. Treat it as a watch item until there is evidence the position is strategic rather than financial; reassess only if Plurilock monetization or contract wins validate the cross-holdings.
• Set an alert for ZENA’s next quarterly filing: if share count growth is outpacing revenue or gross margin slips, exit any long bias immediately; if both improve, the name can work as a tactical momentum trade rather than a structural compounder.